| __timestamp | Catalyst Pharmaceuticals, Inc. | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 10117774 | 79696000 |
| Thursday, January 1, 2015 | 11801342 | 93236000 |
| Friday, January 1, 2016 | 11369941 | 150842000 |
| Sunday, January 1, 2017 | 11375237 | 150643000 |
| Monday, January 1, 2018 | 19919204 | 150252000 |
| Tuesday, January 1, 2019 | 18842752 | 140804000 |
| Wednesday, January 1, 2020 | 16496715 | 34236000 |
| Friday, January 1, 2021 | 16936000 | 35672000 |
| Saturday, January 1, 2022 | 19789000 | 66607000 |
| Sunday, January 1, 2023 | 93150000 | 76363000 |
| Monday, January 1, 2024 | 79048000 |
Data in motion
In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Halozyme Therapeutics, Inc. and Catalyst Pharmaceuticals, Inc. have demonstrated contrasting strategies in their R&D investments.
From 2014 to 2023, Halozyme consistently outspent Catalyst, with its R&D expenses peaking in 2016 at approximately $150 million, nearly 15 times more than Catalyst's spending that year. However, Catalyst's R&D investment surged by over 800% from 2014 to 2023, reaching around $93 million in 2023. This dramatic increase reflects Catalyst's growing focus on expanding its research capabilities.
These trends highlight the dynamic nature of the biotech industry, where strategic R&D investments can drive future growth and innovation. As these companies continue to evolve, their R&D spending will remain a key factor in their competitive positioning.
Comparing Innovation Spending: Bristol-Myers Squibb Company and Catalyst Pharmaceuticals, Inc.
Vertex Pharmaceuticals Incorporated vs Catalyst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Comparing Innovation Spending: GSK plc and Catalyst Pharmaceuticals, Inc.
Research and Development Investment: Bio-Techne Corporation vs Halozyme Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Halozyme Therapeutics, Inc. and Madrigal Pharmaceuticals, Inc.
Analyzing R&D Budgets: Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc.
Analyzing R&D Budgets: Halozyme Therapeutics, Inc. vs Soleno Therapeutics, Inc.
Comparing Innovation Spending: Halozyme Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Research and Development: Comparing Key Metrics for Lantheus Holdings, Inc. and Catalyst Pharmaceuticals, Inc.
TG Therapeutics, Inc. vs Catalyst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
R&D Spending Showdown: Catalyst Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.
R&D Insights: How Catalyst Pharmaceuticals, Inc. and MannKind Corporation Allocate Funds